Alcidion Group Limited (AU:ALC) has released an update.
Alcidion Group Limited reported a positive Q3 with new sales totaling $6.0M and a 2% increase in sold and renewal revenue at $37.4M, alongside significant cost savings initiatives expected to yield $6.4M annually. The company also secured key NHS Trust contracts, bolstering its market presence, and anticipates a strong Q4 with expected positive cashflow, underpinned by a solid cash balance of $6.5M and no debt.
For further insights into AU:ALC stock, check out TipRanks’ Stock Analysis page.
